Last reviewed · How we verify
Piroxicam-Beta-Cyclodextrin
Piroxicam-beta-cyclodextrin is a nonsteroidal anti-inflammatory drug (NSAID) formulated with beta-cyclodextrin to improve solubility and bioavailability, inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation.
Piroxicam-beta-cyclodextrin is a nonsteroidal anti-inflammatory drug (NSAID) formulated with beta-cyclodextrin to improve solubility and bioavailability, inhibiting cyclooxygenase (COX) enzymes to reduce prostaglandin synthesis and inflammation. Used for Rheumatoid arthritis, Osteoarthritis, Acute musculoskeletal pain and inflammation.
At a glance
| Generic name | Piroxicam-Beta-Cyclodextrin |
|---|---|
| Also known as | Cycladol (20mg) capsule |
| Sponsor | Universidade Federal de Sergipe |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
Piroxicam is a non-selective COX inhibitor that blocks both COX-1 and COX-2 enzymes, thereby reducing the production of pro-inflammatory prostaglandins and providing analgesic, anti-inflammatory, and antipyretic effects. The beta-cyclodextrin complexation enhances the drug's aqueous solubility and absorption, potentially improving its pharmacokinetic profile compared to conventional piroxicam formulations.
Approved indications
- Rheumatoid arthritis
- Osteoarthritis
- Acute musculoskeletal pain and inflammation
Common side effects
- Gastrointestinal upset (dyspepsia, nausea)
- Abdominal pain
- Headache
- Dizziness
- Gastric ulceration
- Renal impairment
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |